BR112019020911A2 - Tratamento de doenças inflamatórias intestinais com compostos 2?-fucosilactose - Google Patents

Tratamento de doenças inflamatórias intestinais com compostos 2?-fucosilactose Download PDF

Info

Publication number
BR112019020911A2
BR112019020911A2 BR112019020911-5A BR112019020911A BR112019020911A2 BR 112019020911 A2 BR112019020911 A2 BR 112019020911A2 BR 112019020911 A BR112019020911 A BR 112019020911A BR 112019020911 A2 BR112019020911 A2 BR 112019020911A2
Authority
BR
Brazil
Prior art keywords
fucosylactose
ibd
compound
day
fact
Prior art date
Application number
BR112019020911-5A
Other languages
English (en)
Portuguese (pt)
Inventor
L. Morrow Ardythe
A. Denson Lee
S. Newburg David
Original Assignee
Children´S Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children´S Hospital Medical Center filed Critical Children´S Hospital Medical Center
Publication of BR112019020911A2 publication Critical patent/BR112019020911A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112019020911-5A 2017-04-07 2018-04-07 Tratamento de doenças inflamatórias intestinais com compostos 2?-fucosilactose BR112019020911A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482840P 2017-04-07 2017-04-07
US62/482,840 2017-04-07
PCT/US2018/026631 WO2018187792A1 (en) 2017-04-07 2018-04-07 Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds

Publications (1)

Publication Number Publication Date
BR112019020911A2 true BR112019020911A2 (pt) 2020-05-12

Family

ID=63712677

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019020911-5A BR112019020911A2 (pt) 2017-04-07 2018-04-07 Tratamento de doenças inflamatórias intestinais com compostos 2?-fucosilactose

Country Status (8)

Country Link
US (2) US20200129534A1 (https=)
EP (1) EP3606535A4 (https=)
JP (3) JP2020513014A (https=)
CN (1) CN110730665A (https=)
AU (2) AU2018250337B2 (https=)
BR (1) BR112019020911A2 (https=)
CA (1) CA3059265A1 (https=)
WO (1) WO2018187792A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021111422A1 (en) * 2019-12-06 2021-06-10 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
CN111698994A (zh) 2017-11-30 2020-09-22 格礼卡姆股份公司 治疗小麦敏感性的hmo混合物
BE1027078A9 (nl) 2019-02-25 2020-09-28 Nutribam Bvba Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid
WO2020174386A1 (en) 2019-02-25 2020-09-03 Nutribam Bvba Composition, food supplement and method for supporting and/or improving intestinal health
EP4058031A4 (en) * 2019-11-14 2023-11-08 Glycom A/S SYNTHETIC COMPOSITION FOR BALANCING THE BALE ACID PROFILE IN THE INTESTINAL
CN111588726A (zh) * 2020-04-28 2020-08-28 南开大学 2′-岩藻糖基乳糖调节宿主肠道菌群及增强肠屏障的应用
CN116615203B (zh) * 2020-12-11 2025-03-07 帝斯曼知识产权资产管理有限公司 改进的益生元制剂
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
WO2023102071A1 (en) * 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
US20250213600A1 (en) 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
CN119842563B (zh) * 2025-03-17 2025-06-06 昆明医科大学第一附属医院(云南省皮肤病医院) 多尔氏菌emf18-06b1d及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451462B1 (en) * 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
WO2012009315A2 (en) * 2010-07-12 2012-01-19 The Regents Of The University Of California Bovine milk oligosaccharides
US20120020941A1 (en) * 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
WO2013154725A1 (en) * 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use
EP2687845A1 (en) * 2012-07-20 2014-01-22 Nestec S.A. Fucose as a biomarker for gut immunity
PL3212198T3 (pl) * 2014-10-29 2021-08-23 Glycom A/S Syntetyczna kompozycja i sposób promowania gojenia się błony śluzowej
AU2016208455A1 (en) * 2015-01-23 2017-06-15 Société des Produits Nestlé S.A. Nutritional composition useful in the treatment of IBD patients
EP3862002A1 (en) * 2015-01-26 2021-08-11 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
US10751354B2 (en) * 2015-09-14 2020-08-25 Glycom A/S Synthetic composition for microbiota modulation

Also Published As

Publication number Publication date
US20200129534A1 (en) 2020-04-30
CA3059265A1 (en) 2018-10-11
EP3606535A1 (en) 2020-02-12
US20220133758A1 (en) 2022-05-05
JP2020513014A (ja) 2020-04-30
EP3606535A4 (en) 2020-12-16
AU2024203194A1 (en) 2024-05-30
AU2018250337B2 (en) 2024-02-15
WO2018187792A1 (en) 2018-10-11
JP2025041753A (ja) 2025-03-26
JP2023052629A (ja) 2023-04-11
AU2018250337A1 (en) 2019-10-24
CN110730665A (zh) 2020-01-24

Similar Documents

Publication Publication Date Title
US20220133758A1 (en) Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
Celiberto et al. Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome
Dolan et al. Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases
Milani et al. The human gut microbiota and its interactive connections to diet
Caenepeel et al. how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease
Cresci et al. Gut microbiome: what we do and don't know
Durchschein et al. Diet therapy for inflammatory bowel diseases: The established and the new
Zheng et al. Gut microbiota and inflammatory bowel disease: The current status and perspectives
Turner et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence‐based consensus guidelines
Suez et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota
US9386793B2 (en) Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
Franzin et al. Microbiota and drug response in inflammatory bowel disease
Chen et al. 2′-Fucosyllactose promotes the production of short-chain fatty acids and improves immune function in human-microbiota-associated mice by regulating gut microbiota
Taguer et al. The complex interplay of diet, xenobiotics, and microbial metabolism in the gut: Implications for clinical outcomes
Melton et al. Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease
Cenit et al. Gut microbiota and risk of developing celiac disease
Wang et al. Gut microbiota as a modulator of paneth cells during parenteral nutrition in mice
WO2017000868A1 (zh) 一种组合包在制备用于改善和治疗人类小胖威利综合症的食品、药品、保健品、营养品中的应用
Laing et al. An update on the role of gut microbiota in chronic inflammatory diseases, and potential therapeutic targets
Lewis et al. A review of the epidemiology of inflammatory bowel disease with a focus on diet, infections and antibiotic exposure
Abraham et al. Prebiotics and probiotics in inflammatory bowel disease (IBD)
BR122024023543A2 (pt) Composição farmacêutica, kit e usos de compostos 2'-fucosilactose no tratamento de doenças inflamatórias intestinais
Sharma et al. Current update and future directions on gut microbiome and nephrolithiasis
US20210268037A1 (en) Anaerostipes hadrus for use in promoting health
Han et al. The utilization of oral feeding in pediatric pancreatitis: a randomized controlled study

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024023543-9 PROTOCOLO 870240096760 EM 12/11/2024 11:08.

B09B Patent application refused [chapter 9.2 patent gazette]